Table 3.
Postprocedural Adverse Events in Study Patients (N = 45)
| Adverse Event | NOAC Group, n = 18, No. (%) | DAPT Group, n = 27, No. (%) |
|---|---|---|
| All‐cause death | 2 (11) | 5 (19) |
| CV death | 0 (0) | 3 (11) |
| Stroke/TIA | 0 (0) | 0 (0) |
| Nonfatal MI | 0 (0) | 1 (4) |
| Major bleeding | 3 (17) | 3 (11) |
| Device embolization | 0 (0) | 0 (0) |
| Device‐related thrombus after 45 d | 0 (0) | 0 (0) |
| Peri‐device flow >5 mm after 45 d | 0 (0) | 0 (0) |
| Intracardiac thrombi after 45 d | 0 (0) | 0 (0) |
Abbreviations: CV, cardiovascular; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NOAC, novel oral anticoagulant; TIA, transient ischemic attack.